Market access fundamentals are consistent across therapies: define payer-relevant value, anticipate affordability and uncertainty, and make implementation work in the real care pathway. What changes by asset type is where access most commonly breaks and which stakeholder becomes the effective gatekeeper. Oncology and immunology can break on fast-moving comparators, pathway placement, and biomarker logistics. Rare disease can break on diagnosis, small-sample uncertainty, and continuation criteria. Vaccines and prevention can break on policy endorsement, procurement, delivery logistics, and uptake execution. Cell and gene therapies can break on budget shock, durability uncertainty, and site readiness. Combination therapies and companion diagnostics can break at the seams between testing, prescribing, and payment.
15.1 Oncology and Immunology: Rapid Innovation and Complex Pathways
Oncology and immunology are defined by rapid innovation, heterogeneous patients, and complex care pathways. Access is rarely a single national decision. It is a sequence of gates: payer or HTA assessment, hospital formulary inclusion, pathway placement, site-of-care economics, prior authorization operations, and diagnostic infrastructure. A product can be “covered” and still underperform if it is not embedded in pathways, if testing is slow or unreimbursed, or if provider economics make administration unattractive.
Decision chain: Start by identifying the dominant payment route. For oral oncology and many self-injectable immunology products, access is shaped by pharmacy benefit placement, tiering, and utilization management. For infused or clinic-administered therapies, access is shaped by medical benefit policy plus hospital and infusion-site adoption. Then map the secondary gates that determine real use: hospital P&T committees, oncology pathway committees, integrated delivery system protocols, and the operational rules that turn policies into approvals and paid claims. In oncology, add the diagnostic gate: who orders biomarker tests, where they are run, what assays are accepted, and how results flow into documentation payors can verify.
Value proof: Payors and HTA bodies test three questions. First, what is the relevant comparator in the real pathway for this line of therapy and biomarker status. Second, are outcomes meaningful to patients and clinicians, not only statistically significant. Third, how will results translate to routine practice, where sequencing, monitoring, and adherence differ from trials. In oncology, overall survival and quality of life are the most persuasive outcomes, but decisions often rely on earlier endpoints such as progression measures, response rates, and time-to-event signals. In immunology, payors often focus on outcomes that connect to utilization and persistence: flare reduction, steroid-sparing effects, functional outcomes, and safety and tolerability that influence long-term use.
Comparator volatility is the defining technical challenge. A pivotal trial can be designed against a regimen that becomes outdated by launch, or local practice can differ materially from the study comparator. Build a comparator plan early: define the likely real comparator by market and line of therapy, specify the indirect comparison method when head-to-head data are absent, and document which assumptions are most fragile. Define refresh triggers such as competitor approvals, guideline updates, biosimilar entry, and major pathway updates in top accounts. When the comparator shifts, update the value narrative and the economic assumptions quickly, because payors interpret stale comparators as credibility risk.
Typical controls: Uncertainty and affordability pressure are usually expressed as administrable rules rather than binary denial. These controls become barriers when definitions are vague or documentation requirements do not match clinic workflow.
- Biomarker gating: coverage tied to documented test results, often with accepted assay requirements.
- Line-of-therapy positioning:
- Pathway placement:
- Site-of-care steering:
- Continuation rules:
Operational mechanics: Two workstreams are launch-critical. The first is testing readiness. If biomarker testing is not available, reimbursed, timely, and documentable, eligible patients never enter the treatment funnel. Map the test pathway end-to-end: ordering, lab network, turnaround time, result format, and payer-acceptable documentation. Track testing rate, turnaround time, and documentation completeness as access KPIs. The second workstream is provider economics and workflow. For buy-and-bill products, reimbursement adequacy is necessary but not sufficient; payment timing, denial risk, and administrative burden determine whether providers are willing to adopt. If sites experience repeated denials or slow reimbursement, they will avoid prescribing or delay ordering even when policy is supportive.
Convert nuance into workable criteria. Create a short criteria translation brief that turns clinical selection logic into verifiable proof points: biomarker result, disease status, prior therapy history, and specialist attestation where needed. Define edge cases explicitly (contraindication, intolerance, treatment interruption, mixed response) so exceptions do not become ad hoc. If renewal criteria exist, align them to measures clinics can capture in routine care and define acceptable documentation sources so renewal does not become a denial engine.
Early warnings: Watch comparator drift, pathway placement, denial reasons, and time to start therapy. In oncology, low testing can masquerade as low demand, so monitors start together with testing rates. In immunology, tightening step edits and renewal hurdles often precede share loss; detect these shifts in policy monitoring and denial data before they show up in prescriptions or persistence.
15.2 Rare Diseases and Ultra-Orphan Therapies
Rare disease access is dominated by denominator control, uncertainty management, and feasibility. Patient numbers are small, evidence may be based on limited trials, and diagnosis journeys are often long and uneven. Payors worry about diagnostic uncertainty expanding the eligible population, durability uncertainty for long-term funding, and continuation risk when response is difficult to measure. In many rare diseases, the binding constraint is not the reimbursement decision itself but the ability to identify eligible patients reliably and deliver therapy through limited specialist capacity.
Decision chain: Identify who authorizes first use and who authorizes continuation. Many payors separate initial approval from renewal approval, sometimes with different reviewers and documentation standards. Public systems may approve conditionally with reassessment; private systems often use detailed prior authorization and renewal rules. Map the care network: which specialists confirm diagnosis, which centers treat, how referrals work, and which documents are required for first-pass approval. If the system relies on center-of-excellence delivery, the center network becomes part of access, not just “implementation.”
Value proof: Evidence must be precise and transparent. Reviewers probe endpoint meaning, bias, and comparability to natural history. Your strongest position is a coherent patient definition, a meaningful outcome, and a credible baseline trajectory. When randomized data are limited, natural history cohorts and registries can add context, but state limitations plainly: selection bias, missingness, representativeness, and measurement variability across sites. Avoid broad claims that force payors to defend an open-ended denominator. Instead, define where benefit is clearest and what appropriate use looks like in practical terms.
Typical controls: Access is commonly shaped through strict eligibility and explicit continuation rules.
- Specialist prescribing:
- Diagnostic confirmation:
- Monitoring:
- Continuation criteria:
Operational mechanics: Treat patient finding as part of market access. Build a diagnosis and referral map that answers who suspects the disease, which tests are used, where testing occurs, how referrals flow, and where delays occur. Then build an authorization documentation pack clinics can submit with minimal rework: required test results, diagnosis confirmation note, baseline functional measures, prior treatment history, and the proof points the payor uses to apply criteria. Standardize formats so clinics are not reinventing submissions and payors are not interpreting heterogeneous documentation inconsistently.
Continuation criteria is the most important design point. Choose endpoints that are measurable in routine care, clinically meaningful, and aligned to the expected time to respond. Define meaningful change thresholds, how missing data is handled, and what happens in edge cases such as intercurrent illness or delayed follow-up. If a payor proposes an endpoint that is not feasible, propose an alternative that still protects payer risk but avoids false discontinuation driven by measurement failure.
Convert uncertainty into a time-bound plan. If durability is the binding concern, propose a post-launch evidence program tied to reassessment: endpoints, data source, capture workflow, and what will be available by the review date. Avoid vague registry promises. Define site burden and reporting cadence. In rare diseases, missed commitments are remembered and often result in tighter access at reassessment even when clinical value is accepted.
Early warnings: Monitor diagnosis rate, exception volume, renewal denials, and center capacity. A sudden rise in diagnosed patients can trigger payer concern about denominator expansion. If renewal denials rise, distinguish clinical non-response from documentation and measurement gaps that can be fixed. Track time from diagnosis confirmation to first dose; delays here often reflect referral bottlenecks, site scheduling, or documentation rework, not payer intent.
15.3 Vaccines and Preventive Therapies
Vaccines and preventive therapies are evaluated and purchased differently from treatment products. Value is population-level and often public, while costs are immediate and benefits accrue through avoided disease, avoided outbreaks, and reduced downstream utilization. Access therefore hinges on policy endorsement, funding and procurement decisions, delivery infrastructure, and uptake execution. A favorable recommendation can still underdeliver if supply is unreliable, delivery settings are constrained, or uptake falls short of assumptions.
Decision chain: Map the policy and purchasing sequence. In many markets, immunization advisory bodies recommend, budget owners fund, and procurement bodies purchase. In private segments, coverage is shaped by mandates, benefit design, and delivery settings such as pharmacies, schools, workplaces, and primary care. Define who sets eligibility: age bands, risk groups, boosters, catch-up cohorts, and co-administration rules. Also define who controls logistics: cold chain requirements, packaging, ordering and inventory systems, and supply allocation rules during constrained periods.
Value proof: Prevention value stories require three pillars: disease burden and population impact, program feasibility, and budget predictability. Models must state assumptions on uptake, waning, boosters, and campaign timing. Many decision makers discount distant benefits, so include near-term outcomes where credible, such as avoided hospitalizations and capacity relief during peak seasons. Tie feasibility to delivery: dose schedule complexity, co-administration compatibility, staffing burden, and expected wastage. A preventive product is judged not only on efficacy but also on whether a system can deliver it reliably at scale.
Typical controls: Access is usually shaped through schedule design, procurement terms, and prioritization rather than prior authorization.
- Schedule inclusion:
- Procurement:
- Delivery settings:
- Prioritization:
Operational mechanics: Delivery is the access workstream. Cold chain, ordering and inventory processes, staffing, appointment capacity, and wastage determine real cost and coverage. Wastage is frequently underestimated; include it explicitly in budget assumptions and propose mitigation through packaging choices, inventory controls, and scheduling practices. Plan for implementation lag between procurement decisions and real administration, and align reporting so decision makers can see coverage, wastage, and supply constraints in one view.
Uptake execution is inseparable from access. Build a realistic uptake plan that reflects delivery channels: reminders, recall systems, co-administration practices, workplace or school campaigns, and community outreach. Equity is central because prevention benefits depend on broad, balanced coverage. If uptake concentrates in high-resource populations, population impact underperforms and scrutiny rises. Design delivery routes that reduce friction for underserved groups and monitor coverage gaps early so program design can be adjusted.
Early warnings: Track supply continuity, delivery bottlenecks, wastage, and coverage rates versus assumptions. Watch geographic variation and uptake gaps in underserved communities. If coverage rates are below plan, update impact projections and adjust delivery strategy quickly; defending unrealistic uptake assumptions erodes credibility and can harm future procurement decisions.
15.4 Cell and Gene Therapies and One-Time Curative Treatments
Cell and gene therapies compress long-term value into an up-front cost and a complex delivery event. Payors face budget shock and durability uncertainty, often amplified by member churn. Providers face logistics, site qualification, chain-of-identity and chain-of-custody requirements, and intensive patient coordination. Access succeeds only when value, financing, and operations are designed as one system, because any weakness becomes the payor’s rationale for strict gating.
Decision chain: These therapies are commonly gated by center qualification, strict eligibility, and defined follow-up. Map who authorizes coverage, who approves sites, what documentation is required for first-pass approval, and what budget pays in practice. In some systems, special funds or carve-outs exist; in others, cost sits with hospitals, which then restrict through formularies and scheduling. Clarify early where the budget shock will be felt and what approvals are required to avoid repeated resubmissions that delay care.
Value proof: The core payer question is durability. Trials may be small and follow-up limited at launch. Present durability assumptions transparently, show sensitivity ranges, and define a credible post-launch evidence plan that reduces uncertainty before reassessment. If outcomes-linked terms are contemplated, choose endpoints that are measurable with available data and occur within a timeframe relevant to payer budgeting. Address safety-in-practice and long-term monitoring feasibility, because systems will not accept commitments that sites cannot execute.
Typical controls: Restrictions are usually both clinical and operational, designed to ensure safe delivery and control early-wave demand.
- Center-of-excellence delivery:
- Eligibility boundaries:
- Diagnostic proof:
- Follow-up:
Operational mechanics: Start with a stock-and-flow view. Stock:Flow:
Financing discussions should follow payer risk, not novelty. Payors may seek payment smoothing, exposure caps, or durability-linked adjustments. Keep designs simple and executable. If outcomes-linked terms are used, define endpoint, data source, measurement window, and reconciliation process up front. When measurement infrastructure is weak, simpler risk controls paired with explicit reassessment windows can reduce variance risk without creating operational failure. Whatever the structure, ensure it does not delay initiation through complex data capture requirements.
Early warnings: Monitor time to authorization, time to scheduling, center throughput, denial reasons, payment delays, and follow-up completion. Low follow-up completion undermines durability narratives and increases tightening risk at review. Also monitor capacity versus demand; if capacity expands after initial constraints, payors may perceive a sudden utilization surge unless you communicate stock-and-flow dynamics clearly.
15.5 Combination Therapies and Companion Diagnostics
Combination therapies and companion diagnostics create access complexity because reimbursement spans multiple components and often multiple budget silos. The regimen’s value depends on correct testing, correct sequencing, and correct co-administration. Access often fails at the seams: the drug is covered but the test is not; one component is restricted; turnaround time is too slow; or documentation requirements create denials despite clinical appropriateness. The access goal is to make the seams explicit and assign owners to each seam.
Combination therapy: a regimen where clinical benefit depends on using two or more agents together, sometimes from different manufacturers.
Companion diagnostic: a test required to identify eligible patients or to avoid harm, often defining reimbursed criteria.
Decision chain: Map three linked gates. Testing gate:Regimen gate:Payment gate:
Value proof: Demonstrate incremental regimen benefit versus real comparators, not only versus each component. Reviewers ask whether the combination improves meaningful outcomes enough to justify added cost, toxicity, and monitoring burden. Translate trial regimens into routine practice feasibility: expected adherence, discontinuation patterns, monitoring requirements, and site-of-care impact. If benefit depends on strict testing discipline, show how the pathway will achieve that discipline in practice and how results will be documented for payer review.
Typical controls: Expect test documentation requirements, sequencing rules, and pathway controls. Payors may specify accepted assays or labs, define line-of-therapy tightly, and impose renewal rules when response is variable. In hospital settings, procurement and pathway governance can steer combinations through preferred purchasing and protocol design, which can effectively block use even when the drug is technically covered.
Operational mechanics: Treat diagnostic readiness as launch-critical. Ensure a clear reimbursement route for the test, that results return fast enough to influence clinical decisions, and that results flow into documentation payors can verify. Provide clinic-ready guidance that specifies what to submit and in what format. If multiple assays exist, define equivalence and acceptance to prevent “wrong test” denials. Monitor testing rates and equity; lower testing in underserved settings becomes a structural access barrier and can also undermine the regimen’s real-world value.
Model economics at the regimen level. Even when negotiations are product-level, payors assess total regimen cost, administration burden, and monitoring requirements. Build scenarios that reflect real-world switching and discontinuation, because regimen economics change when patients discontinue one component, switch due to toxicity, or move across sites of care. Align contracting posture to the regimen story: what access improvement you are buying with what concession, and what operational commitments are required to make the regimen workable.
Early warnings: Track test reimbursement denials, test turnaround time, the share of eligible patients tested, regimen pathway placement, and component-level restrictions. Seam failures usually appear first as delays and denials, not as explicit policy changes. When detected early, many can be fixed with clearer documentation standards, payer operations engagement, and site workflow improvements.
Across all special assets, scale comes from standardization. Keep one source of truth for population definitions, comparator logic, and criteria. Maintain a decision log of concessions and give-gets. Run a fixed early-launch cadence tying denials, delays, and pathway changes to owners and fixes within days.
Special asset types reward the same discipline as standard assets, but their failure modes are more predictable. Identify the effective gatekeeper, build evidence that matches the payor’s risk question, translate nuance into administrable criteria, and design operational readiness for the real pathway. Done consistently, these categories become manageable rather than exceptional.
